Publications by authors named "Angelo Margaritis"
Article Synopsis
- Nucleic acid-amplification testing (NAT) is a method used to check blood donations for harmful viruses to keep people safe.
- In 2019, a global survey showed that countries mostly followed government rules for testing blood for viruses like HIV and hepatitis.
- The results indicated a trend towards using individual samples for testing instead of larger pools to improve safety in blood donations.
Article Synopsis
- The project reviewed the global use of nucleic acid amplification testing (NAT) in blood services to detect viral and parasite nucleic acids and reduce transfusion-related infections.
- A survey conducted among members of the International Society of Blood Transfusion revealed a significant increase in NAT adoption over the past decade, with data showing low but notable positivity rates for various viruses in blood donations.
- While NAT has enhanced blood transfusion safety worldwide, there is a call to address economic barriers that prevent some regions from implementing these important testing methods.
Background: Blood services are required to maintain repositories of frozen samples for confirmation of results and/or retrospective testing. The Australian Red Cross Blood Service archives donor samples in plasma preparation tubes (PPTs). This study aims to evaluate the effect of freeze-thawing and extended frozen storage on the ability to detect human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) using blood donation screening assays in samples stored in PPTs.
View Article and Find Full Text PDFBackground: We present an analysis of the first 2 years of hepatitis B virus (HBV) nucleic acid testing (NAT) of the Australian donor population.
Study Design And Methods: Between July 5, 2010, and July 4, 2012, all blood donations were screened for HBV DNA and hepatitis B surface antigen (HBsAg). Donors who tested HBsAg negative but HBV NAT positive were assessed as occult hepatitis B infections (OBI) if reactive for antibodies to HBV core antigen (anti-HBc).
Background: Recently developed nucleic acid testing (NAT) assays incorporating simultaneous detection of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) have made HBV NAT screening more feasible for blood services. This study compared the performance of two "multiplex" NAT assays and their automated testing platforms.
Study Design And Methods: The HBV NAT yield rate was estimated by testing 10,397 Hong Kong (HK) donor samples concurrently on the PROCLEIX ULTRIO (Ultrio) assay as individual donor samples with the TIGRIS and on the cobas TaqScreen multiplex (cobas MPX) test in pools of 6 with the cobas s 201.
Background: Traditional strategies for clarifying the antibody status of donors giving repeatedly reactive (RR) results on primary screening immunoassays (IA1) have usually involved direct testing by immunoblot. However, such strategies can generate nonspecific in determinate results. The aim of this report is to present the results of an alternative strategy based on the use of sequential immunoassays (SI) before immunoblot testing.
View Article and Find Full Text PDF